10-Q: CONMED Q3 2025: Sales Up, Profit Down Amid Cost Pressures

CONMED Corporation reported increased net sales for Q3 2025 and the nine months ended September 30, 2025, but experienced significant declines in net income and gross profit margins due to higher costs, inventory write-offs, and advisory/consulting fees.

Summary

• Net sales increased by 6.7% to $337.9 million for the three months ended September 30, 2025, and by 4.2% to $1,001.5 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Net income significantly decreased to $2.9 million ($0.09 diluted EPS) for the three months and $30.3 million ($0.97 diluted EPS) for the nine months ended September 30, 2025, from $49.0 million ($1.57 diluted EPS) and $98.7 million ($3.17 diluted EPS) in the prior year periods, respectively.
• Gross profit margins declined to 49.2% (from 56.5%) for the three months and 53.1% (from 55.6%) for the nine months, primarily due to $19.7 million in inventory, equipment, tooling, and patent write-offs and $12.3 million in consulting fees for supply chain improvements.
• Selling and administrative expenses increased significantly, driven by $12.2 million in compensation for the former CEO's advisory services and $8.5 million in operational optimization consulting fees.
• The company entered into an eighth amended and restated senior credit agreement on June 10, 2025, including a $100.0 million term loan and a $650.0 million revolving credit facility.
• The Board authorized a $150.0 million share repurchase program, modifying a prior program, and suspended dividend payments.
• The DOJ closed its investigation into potential royalty payment issues without prosecution.
• The Italian government granted a 75% discount on the medical device tax for 2015-2018, and the company made the payment in September 2025.

Sentiment

Score: 3

Explanation: Despite modest sales growth, net income and gross profit margins saw substantial declines due to significant write-offs, increased operational costs, and advisory fees. The suspension of dividends and the non-renewal of a key distribution agreement add to the negative sentiment, overshadowing the resolution of legal and tax matters.

Positives

• Net sales grew by 6.7% in Q3 2025 and 4.2% year-to-date 2025, reaching $337.9 million and $1,001.5 million, respectively.
• Orthopedic surgery sales increased 5.9% in Q3 and 3.0% year-to-date, driven by procedure-specific, foot and ankle, and BioBrace product offerings.
• General surgery sales increased 7.3% in Q3 and 5.1% year-to-date, primarily due to growth in AirSeal, Buffalo Filter, and biliary product offerings.
• Capital sales returned to growth during the three months ended September 30, 2025.
• The U.S. Department of Justice (DOJ) closed its investigation into potential royalty payment issues without requiring further action or prosecution, civilly or criminally.
• The Italian government granted a 75% discount on the medical device tax for the years 2015-2018, leading to a resolution of the liability with payment submitted in September 2025.
• Net cash provided by operating activities increased slightly to $124.4 million for the nine months ended September 30, 2025, compared to $123.6 million in the prior year.
• The company was in full compliance with all covenants and restrictions of its eighth amended and restated senior credit agreement as of September 30, 2025.
• Interest expense decreased due to lower weighted average borrowings outstanding and lower weighted average interest rates during 2025.

Negatives

• Net income plummeted by 94.2% to $2.9 million for the three months and by 69.3% to $30.3 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Gross profit margins significantly decreased by 730 basis points to 49.2% in Q3 and by 250 basis points to 53.1% year-to-date.
• The company incurred $19.7 million in write-offs for inventory, equipment, tooling, and patents due to the cancellation of planned new product lines and discontinuation of certain catalog numbers.
• Selling and administrative expenses increased substantially, partly due to $12.2 million in cash and stock-based compensation for advisory services from the former Chief Executive Officer and $8.5 million in operational optimization consulting fees.
• Fair value adjustments to contingent consideration resulted in a $3.5 million expense for the nine months ended September 30, 2025, a significant negative swing compared to a $42.3 million income in the prior year period.
• The company announced it will not be renewing its Distribution Agreement for the Gore VIABIL Biliary Endoprosthesis after December 31, 2026, which contributed $44.1 million in net sales with an approximate 38% gross profit margin in the nine months ended September 30, 2025.
• Dividend payments have been suspended by the Board of Directors.
• Higher effective tax rates were recorded for the three months (33.1% vs 13.2%) and nine months (27.6% vs 17.4%) ended September 30, 2025, primarily due to lower income and non-deductible fair value adjustments.

Risks

• General economic and business conditions, including potential economic downturns, supply chain challenges and constraints, inflation, and increased interest rates.
• Trade protection measures, tariffs, and other border taxes, as well as import or export licensing requirements.
• Compliance with and changes in regulatory requirements.
• Failure of enterprise-wide software programs or information technology systems, or potential disruption associated with updating or implementing new systems, including cybersecurity breaches.
• Impacts from pandemics and health crises.
• Potential for United States or foreign regulatory and/or administrative agencies to initiate enforcement actions.
• Challenges and uncertainties inherent in product research and development, and the uncertain impact, outcome, and cost of ongoing and future clinical trials and market studies.
• Competition, changes in customer preferences, and changes in technology.
• Cyclical customer purchasing patterns due to budgetary, staffing, and other constraints.
• Environmental compliance risks, including the availability and costs associated with Ethylene Oxide (EtO) sterilization.
• Ability to attract, motivate, and retain employees at all levels of the company.
• Availability, terms, and deployment of capital; current and future levels of indebtedness and capital spending.
• Changes in foreign exchange and interest rates.
• Ability to evaluate, finance, and integrate acquired businesses, products, and companies.
• Risk of a lack of allograft tissues due to reduced donations or quality issues.
• Ability to defend and enforce intellectual property, including risks related to theft or compromise in international operations.
• Risk of patent, product, and other litigation, as well as associated costs.
• Weather-related events which may disrupt operations.
• Potential for future material enforcement actions or significant costs from inquiries or investigations.
• Exposure to significant product liability claims.
• Future compliance or remedial obligations related to environmental laws could have a material adverse effect.
• The non-renewal of the Gore VIABIL distribution agreement will impact future net sales and gross profit.

Future Outlook

Management believes that cash flow from operations, cash and cash equivalents on hand, and available borrowing capacity under the senior credit agreement will be adequate to meet anticipated operating working capital requirements, debt service, capital expenditures, dividend payments, and common stock repurchases in the foreseeable future. The company expects to repurchase at least $25.0 million in shares annually beginning in 2026. The Distribution Agreement for the Gore VIABIL device will not be renewed after December 31, 2026. Due to the macro-economic environment, inflation, and supply chain challenges, the company may need to take further steps to reduce costs or refinance debt. New accounting pronouncements are being evaluated, with some expected to impact disclosures but not consolidated financial statements.

Management Comments

• "We continue to monitor our spending and expenses in light of these factors [macro-economic environment, inflation, supply chain challenges]."
• "Management believes that cash flow from operations, including cash and cash equivalents on hand and available borrowing capacity under our eighth amended and restated senior credit agreement, will be adequate to meet our anticipated operating working capital requirements, debt service, funding of capital expenditures, dividend payments and common stock repurchases in the foreseeable future."
• "Management believes we could access capital markets, as necessary, to fund future business acquisitions."
• "We may need to take further steps to reduce our costs, or to refinance our debt."

Industry Context

The medical technology industry continues to face challenges from the macro-economic environment, including inflationary pressures and ongoing supply chain disruptions, which are impacting manufacturing and operating costs. Regulatory scrutiny, such as the Physician Payments Sunshine Act and anti-bribery laws like the FCPA, remains a significant factor for medical device manufacturers operating globally. CONMED's focus on orthopedic and general surgery product lines, with a substantial portion of revenue from single-use products, aligns with broader trends in minimally invasive surgery and recurring revenue models within the medtech sector.

Corporate Governance

Legal Proceedings

• The U.S. Department of Justice (DOJ) informed the company on September 5, 2025, that it was declining to prosecute, civilly or criminally, for any conduct related to potential issues with certain royalty payments to surgeons involved in design teams, and closed its investigation.
• The Italian medical device tax for 2015-2018 was resolved: the Italian Constitutional Court determined the tax constitutional on July 22, 2024, and Decree-Law No. 95, which became law in August 2025, granted a 75% discount on amounts due. The company submitted payment in September 2025.
• The company is subject to ongoing exposure to information requests, subpoenas, or warrants from government agencies (e.g., SEC, DOJ, FDA), product liability claims, patent infringement, environmental laws, and negligence claims in the ordinary course of business.

Stakeholder Impact

• Shareholders: Suspension of dividends removes a direct income stream, while the new share repurchase program offers potential for future value appreciation. The significant drop in net income and EPS may negatively impact investor confidence and stock valuation.
• Employees: Potential for cost reduction measures due to macro-economic environment and operational optimization efforts could impact employment or compensation.
• Customers: Continued product offerings in orthopedic and general surgery, but the discontinuation of certain catalog numbers and the non-renewal of the Gore VIABIL distribution agreement after December 31, 2026, may affect specific customer segments or product availability.
• Creditors: The company remains in full compliance with debt covenants under its new senior credit agreement, indicating stability in its ability to meet debt obligations.
• Suppliers: Ongoing supply chain challenges may impact relationships and procurement processes.

Next Steps

• Continue monitoring spending and expenses in light of macro-economic factors, inflation, and supply chain challenges.
• Evaluate the impact of new accounting standards (ASU 2025-06, 2024-03, 2023-09) on financial statements and disclosures.
• Repurchase at least $25.0 million in shares annually beginning in 2026 under the Modified Program.
• Potentially take further steps to reduce costs or refinance debt if macro-economic conditions persist.
• The Distribution Agreement for the Gore VIABIL device will not be renewed after December 31, 2026, requiring strategic adjustments for this product line.

Key Dates

Recommendation

The significant decline in net income and gross profit margins, driven by substantial write-offs and increased operating costs, indicates fundamental operational challenges. The suspension of dividends removes a key incentive for income-focused investors, and the non-renewal of the Gore VIABIL distribution agreement, which contributed $44.1 million in sales with a 38% gross margin, signals a future revenue headwind. While some legal and tax uncertainties have been resolved, the overall financial performance and outlook suggest a deteriorating investment profile, warranting a "sell" recommendation until a clear path to improved profitability and sustained growth is demonstrated.

Keywords

Medical technology, Surgical devices, Orthopedic surgery, General surgery, SEC filing, 10-Q, Financial results, CONMED, CNMD, Medical equipment, Supply chain, Inflation, Gross margin, Net income, Share repurchase, Convertible notes, Debt, Regulatory compliance, Dividend suspension